Pharmicell Co (A005690) Q4 2024 earnings summary

Executive summary

• Operates two main divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (pharmaceutical intermediates, specialty chemicals).

• 2024 saw strong revenue growth, driven by Bio-Chemical division, especially AI accelerator materials.

• Bio-Medical division remains in deficit due to ongoing R&D, while Bio-Chemical maintains profitability.

Financial highlights

• Revenue for FY2024: KRW 64,851 million, up 15% year-over-year.

• Operating income: KRW 4,656 million, up 259% from previous year.

• Net income: KRW 6,331 million, up 77% year-over-year.

• Gross margin improved to 32.9% from 27.5% year-over-year.

• Cash and equivalents at year-end: KRW 8,261 million.

Outlook and guidance

• Expects further improvement as stem cell therapy market matures and Bio-Chemical division expands output.

• New plant completions and product launches anticipated to drive future growth.